恒瑞医药：瑞维鲁胺片获临床试验批准

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of Rivolumab tablets, a second-generation AR inhibitor, which will be conducted shortly [1] Group 1: Product Development - Rivolumab tablets exhibit stronger AR inhibition compared to first-generation AR inhibitors and do not have agonistic effects [1] - The product was approved for market launch in 2022 for treating high tumor burden metastatic hormone-sensitive prostate cancer (mHSPC) patients [1] Group 2: Market Context - Competing second-generation AR inhibitors such as Enzalutamide, Apalutamide, and Darolutamide are already available in the market [1] - According to EvaluatePharma, the total global sales of similar products are projected to reach approximately $11.037 billion in 2024 [1] Group 3: Investment and R&D - The cumulative R&D investment related to Rivolumab tablets has reached approximately 693 million yuan [1]